Hemostatic sponge

Abstract

The present invention provides a hemostatic composite sponge comprising oxidized cellulose and an essentially gelatin-free bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.

What is claimed is: 
     
         1 . A method for treating an injury in a patient, the method comprising:
 providing a hemostatic porous composite sponge, wherein the hemostatic porous composite sponge comprising a matrix of oxidized cellulose and a bioadhesive material stably associated with at least one surface of the hemostatic porous composite sponge, wherein the bioadhesive material is free of gelatin, the bioadhesive material is present in a range of 2 to 50 mg/cm 2  of the oxidized cellulose, and the bioadhesive material is present in a grid pattern on the hemostatic porous composite sponge;   administering the hemostatic porous composite sponge to a site of the injury; and   maintaining the hemostatic porous composite sponge to the site of the injury for a pharmaceutically sufficient amount of time so that the injury is treated.   
     
     
         2 . The method according to  claim 1 , wherein the injury is selected from the group consisting of a wound, a hemorrhage, a damaged tissue and a bleeding tissue. 
     
     
         3 . The method according to  claim 1 , wherein the bioadhesive material is capable of covalently reacting with tissue of the patient. 
     
     
         4 . The method according to  claim 1 , wherein the bioadhesive material is selected from the group consisting of polyethylene glycol, derivatives of polyethylene glycol, and combinations thereof. 
     
     
         5 . The method according to  claim 1 , wherein the bioadhesive material is reactive polyethylene glycol. 
     
     
         6 . The method according to  claim 1 , wherein the bioadhesive material comprises multiple reactive polyethylene glycols. 
     
     
         7 . The method according to  claim 1 , wherein the grid pattern forms a continuous layer on the surface of the hemostatic porous composite sponge. 
     
     
         8 . The method according to  claim 1 , wherein the bioadhesive material comprises a mixture of two pre-polymers comprising a first cross-linkable component and a second cross-linkable component that cross-links with the first cross-linkable component under reaction enabling conditions, and the second cross-linkable component comprises a polyethylene glycol (PEG) having two or more succinimidyl groups. 
     
     
         9 . A method for treating an injury in a patient, the method comprising:
 providing a hemostatic porous composite sponge, wherein the hemostatic porous sponge comprising a matrix of oxidized cellulose and a material enhancing the adherence of the hemostatic porous composite sponge to an applied tissue stably associated with at least one surface of the hemostatic porous composite sponge, wherein the adherence-enhancing material is essentially free of gelatin, the adherence-enhancing material is present in a range of 2 to 50 mg/cm 2  of the oxidized cellulose, and the adherence-enhancing material is present in a grid pattern on the hemostatic porous composite sponge;   administering the hemostatic porous composite sponge to a site of the injury; and   maintaining the hemostatic porous composite sponge to the site of the injury for a pharmaceutically sufficient amount of time so that the injury is treated.   
     
     
         10 . The method according to  claim 9 , wherein the injury is selected from the group consisting of a wound, a hemorrhage, a damaged tissue and a bleeding tissue. 
     
     
         11 . The method according to  claim 9 , wherein the adherence-enhancing material is capable of covalently reacting with tissue of the patient. 
     
     
         12 . The method according to  claim 9 , wherein the adherence-enhancing material is selected from the group consisting of polyethylene glycol, derivatives of polyethylene glycol, and combinations thereof. 
     
     
         13 . The method according to  claim 9 , wherein the adherence-enhancing material is reactive polyethylene glycol. 
     
     
         14 . The method according to  claim 9 , wherein the adherence-enhancing material comprises multiple reactive polyethylene glycols. 
     
     
         15 . The method according to  claim 9 , wherein the grid pattern forms a continuous layer on the surface of the hemostatic porous composite sponge. 
     
     
         16 . The method according to  claim 9 , wherein the hemostatic porous composite sponge comprises multiple polymers. 
     
     
         17 . The method according to  claim 9 , wherein the adherence-enhancing material comprises a mixture of two pre-polymers comprising a first cross-linkable component and a second cross-linkable component that cross-links with the first cross-linkable component under reaction enabling conditions, and the second cross-linkable component comprises a polyethylene glycol (PEG) having two or more succinimidyl groups. 
     
     
         18 . A method for treating an injury in a patient, the method comprising:
 providing a hemostatic porous composite sponge, wherein the hemostatic porous sponge comprising a matrix of oxidized cellulose and a gelatin-free material enhancing the adherence of the hemostatic porous composite sponge to an applied tissue stably associated with at least one surface of the hemostatic porous composite sponge, wherein the gelatin-free material is present in a range of 2 to 5 mg/cm 2  of the oxidized cellulose, wherein the gelatin-free material is present in an organized pattern on the hemostatic porous composite sponge;   administering the hemostatic porous composite sponge to a site of the injury; and   maintaining the hemostatic porous composite sponge to the site of the injury for a pharmaceutically sufficient amount of time so that the injury is treated.   
     
     
         19 . The method according to  claim 18 , wherein the injury is selected from the group consisting of a wound, a hemorrhage, a damaged tissue and a bleeding tissue. 
     
     
         20 . The method according to  claim 18 , wherein the gelatin-free material is capable of covalently reacting with tissue of the patient. 
     
     
         21 . The method according to  claim 18 , wherein the gelatin-free material is selected from the group consisting of polyethylene glycol, derivatives of polyethylene glycol, and combinations thereof. 
     
     
         22 . The method according to  claim 18 , wherein the gelatin-free material is reactive polyethylene glycol. 
     
     
         23 . The method according to  claim 18 , wherein the gelatin-free material comprises multiple reactive polyethylene glycols. 
     
     
         24 . The method according to  claim 18 , wherein the organized pattern forms a continuous layer on the surface of the hemostatic porous composite sponge. 
     
     
         25 . The method according to  claim 18 , wherein the hemostatic porous composite sponge comprises multiple polymers. 
     
     
         26 . The method according to  claim 18 , wherein the gelatin-free material comprises a mixture of two pre-polymers comprising a first cross-linkable component and a second cross-linkable component that cross-links with the first cross-linkable component under reaction enabling conditions, and the second cross-linkable component comprises a polyethylene glycol (PEG) having two or more succinimidyl groups.